Is Biktarvy mainly suitable for prevention or treatment?

Biktarvy (Biktarvy) is an antiviral drug used for treatment rather than prevention, mainly for patients infected with human immunodeficiency virus (HIV). It is a combination preparation that contains bictegravir (bictegravir), emtricitabine (emtricitabine) and tenofovir alafenamide fumarate (tenofovir Alafenamide), the three drugs work synergistically to effectively inhibit the replication of HIV virus, reduce the viral load in the body, and thereby control the progression of the disease.

The therapeutic effect of Bituvi is reflected in helpingHIV infected people maintain a state of viral suppression and prevent the occurrence and development of AIDS. The drug is indicated for use in adults and adolescents who are new to antiretroviral therapy, as well as in patients already receiving other treatments who need to switch regimens. By adhering to long-term medication, patients can maintain immune system function, reduce the risk of infections and complications, and improve their quality of life.

Although Bitovil has a very strong antiviral effect, it is not used for HIV prevention, such as pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). In the area of u200bu200bHIV prevention, other specific drugs and regimens are often chosen. Bitovil is designed as a treatment to help patients achieve sustained viral suppression, not to prevent an initial viral infection.

In general, Bitovil is an effective treatment drug for HIV infection. It is mainly used for virus control and disease management in patients, rather than as a preventive drug. Its safety and efficacy have been proven through multiple clinical trials, making it one of the important choices in current anti-HIV treatment.

Reference materials:https://www.biktarvy.com/